Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Goodwill (2020 - 2023)

Insight Molecular Diagnostics' Goodwill history spans 4 years, with the latest figure at $9.5 million for Q3 2023.

  • On a quarterly basis, Goodwill fell 49.15% to $9.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was $9.5 million, a 49.15% decrease, with the full-year FY2022 number at $9.2 million, down 50.76% from a year prior.
  • Goodwill hit $9.5 million in Q3 2023 for Insight Molecular Diagnostics, roughly flat from $9.5 million in the prior quarter.
  • Over the last five years, Goodwill for IMDX hit a ceiling of $24.2 million in Q2 2021 and a floor of $9.2 million in Q1 2020.
  • Historically, Goodwill has averaged $13.4 million across 4 years, with a median of $9.5 million in 2023.
  • Biggest five-year swings in Goodwill: surged 163.82% in 2021 and later plummeted 50.76% in 2022.
  • Tracing IMDX's Goodwill over 4 years: stood at $9.2 million in 2020, then skyrocketed by 103.37% to $18.7 million in 2021, then tumbled by 50.76% to $9.2 million in 2022, then increased by 3.26% to $9.5 million in 2023.
  • Business Quant data shows Goodwill for IMDX at $9.5 million in Q3 2023, $9.5 million in Q2 2023, and $9.5 million in Q1 2023.